Relay Therapeutics Income Statement (2019-2026) | RLAY

Income Statement Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
92.80M108.21M108.43M108.81M120.81M121.11M121.48M121.94M123.16M127.46M132.30M133.32M166.89M167.76M170.48M171.69M172.63M173.87M189.21M219.14M
Revenue & cost
Revenue (Quarter)
0.67M0.57M0.42M0.36M0.34M0.25M0.23M0.12M25.20M-0.00M10.01M7.68M0.68M7.00M3.00M0.35M
Operating items
Research & Development (Quarter)
44.97M51.91M51.67M60.51M66.90M67.28M82.83M88.20M81.49M77.50M82.40M91.99M76.62M68.08M73.81M63.90M68.26M55.41M70.56M76.48M
Selling, General & Administrative (Quarter)
14.68M15.55M16.07M17.46M16.07M16.37M19.58M20.12M18.48M16.77M19.80M20.14M19.75M16.90M18.74M13.63M12.13M12.21M11.03M14.69M
Other Operating Expenses (Quarter)
2.00M0.84M-4.59M0.20M3.26M-10.54M-1.00M-2.15M-1.20M-2.07M-1.83M-11.37M
Operating Expenses (Quarter)
61.66M68.29M63.14M78.18M86.24M73.10M101.40M106.17M98.78M92.19M100.37M100.76M96.37M84.98M92.55M77.52M80.39M67.63M81.59M91.17M
Operating Income (Quarter)
-60.99M-67.72M-62.72M-77.81M-85.89M-72.85M-101.18M-106.05M-73.58M-92.20M-90.36M-100.76M-96.37M-84.98M-84.87M-76.85M-80.39M-60.63M-78.59M-90.82M
EBIT (Quarter)
-60.99M-67.72M-62.72M-77.81M-85.89M-72.85M-101.18M-106.05M-73.58M-92.20M-90.36M-100.76M-96.37M-84.98M-84.87M-76.85M-80.39M-60.63M-78.59M-90.82M
Non-operating items
Interest & Investment Income (Quarter)
0.07M-1.72M-8.13M-2.69M1.71M5.37M6.94M-0.28M2.69M3.19M8.95M8.55M8.27M32.04M7.81M7.11M6.41M25.55M-0.17M7.12M
Other Non Operating Income (Quarter)
0.16M0.27M0.68M1.02M1.72M5.35M6.94M7.54M7.84M8.70M8.98M8.54M8.26M8.97M7.80M6.47M6.24M5.74M5.30M7.12M
Non Operating Income (Quarter)
-0.02M0.02M0.01M-0.02M-0.00M-0.01M-0.00M0.00M0.03M-0.00M-0.01M0.00M-0.01M-0.63M-0.17M0.03M0.00M
Net income details
EBT (Quarter)
-61.92M-73.44M-80.07M-92.41M-85.28M-75.06M-100.57M-112.41M-74.27M-107.91M-82.71M-93.56M-88.39M-484.87M-77.97M-73.98M-74.22M-35.09M-79.13M-85.32M
Profit After Tax (Quarter)
-60.83M-67.40M-62.05M-76.79M-84.17M-64.53M-94.24M-98.50M-63.04M-83.50M-81.39M-92.21M-84.26M-78.71M-76.04M-70.38M-73.49M-54.65M-73.46M-85.09M
Income from Continuing Operations (Quarter)
-61.92M-73.44M-80.07M-92.41M-85.28M-75.06M-100.57M-112.41M-74.27M-107.91M-82.71M-93.56M-88.39M-484.87M-77.97M-73.98M-74.22M-35.09M-79.13M-85.32M
Consolidated Net Income (Quarter)
-61.92M-73.44M-80.07M-92.41M-85.28M-75.06M-100.57M-112.41M-74.27M-107.91M-82.71M-93.56M-88.39M-484.87M-77.97M-73.98M-74.22M-35.09M-79.13M-85.32M
Income towards Parent Company (Quarter)
-61.92M-73.44M-80.07M-92.41M-85.28M-75.06M-100.57M-112.41M-74.27M-107.91M-82.71M-93.56M-88.39M-484.87M-77.97M-73.98M-74.22M-35.09M-79.13M-85.32M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-60.83M-67.46M-80.07M-92.41M-85.28M-75.06M-100.57M-112.41M-74.27M-107.91M-82.71M-93.56M-88.39M-484.87M-77.97M-73.98M-74.22M-35.09M-79.13M-85.32M
Additional items
EPS (Basic) (Quarter)
-0.66-0.71-0.74-0.85-0.77-0.67-0.83-0.92-0.61-0.88-0.63-0.70-0.63-3.39-0.46-0.43-0.43-0.20-0.44-0.42
EPS (Diluted) (Quarter)
-0.66-0.71-0.84-0.97-0.77-0.67-0.90-1.00-0.66-0.96-0.74-0.83-0.79-4.32-0.69-0.66-0.66-0.31-0.71-0.76
Shares Outstanding (Quarter)
92.69M95.14M108.29M108.64M110.91M112.23M121.32M121.68M122.23M122.58M130.84M132.82M140.23M142.87M169.23M171.26M172.39M171.59M179.85M202.85M
Shares Outstanding (Diluted) (Quarter)
92.69M95.14M95.14M95.14M110.91M112.23M112.23M112.23M112.23M112.23M112.23M112.23M112.23M112.23M112.23M112.23M112.23M112.23M112.23M112.23M
EBITDA (Quarter)
-60.99M-67.72M-62.72M-77.81M-85.89M-72.85M-101.18M-106.05M-73.58M-92.20M-90.36M-100.76M-96.37M-84.98M-84.87M-76.85M-80.39M-60.63M-78.59M-90.82M
Interest Expenses (Quarter)
1.00M4.00M9.22M11.91M1.10M7.58M6.33M6.08M3.39M18.91M1.30M1.35M0.30M431.93M0.91M4.24M0.24M0.01M0.36M1.61M